Publications

 


  • 218. Prostatakrebs:Wo steht die vorsorge im jahr 2004?

    Recker F, Kwiatkowski M, 2004

    Journal: Schweiz Med Forum
    Reference: 4: 509-512

    paper

  • 217. PSA screening für das prostata-karzinom-ja oder nein?

    Recker F, Kwiatkowski M, 2004

    Journal: Therapeitische Umschau
    Reference: Band 61, heft 6

    paper

  • 216. Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors

    Paris PL, Andaya A, Fridlyand J, et al., 2004

    Journal: Hum. Mol. Genetics
    Reference: 13:1303-1313

    paper

  • 215. Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening

    Finne P, Finne R, Bangma Ch, Hugosson J, Hakama M, Auvinen A, Stenman U-H., 2004

    Journal: Int. J. Cancer
    Reference: 111: 310-315

    paper

  • 214. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/ml or greater (ERSPC, Rotterdam)

    Roobol MJ, van der Cruijsen IW, Schröder FH, 2004

    Journal: Urol
    Reference: 63 (5): 892-899

    paper

  • 213. Update on screening and early detection of prostate cancer

    Otto SJ, de Koning HJ, 2004

    Journal: Curr Opinion in Urol
    Reference: 14:151-156

    paper

  • 212. Potentially advanced malignancies detected by screening for prostate cancer after an interval of 4 years

    Postma R, Roobol MJ, Schröder FH, van der Kwast TH, 2004

    Journal: Cancer
    Reference: 100 (5): 968-975

    paper

  • 211. The value of (-7,-5) pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer

    Bangma CH, Wildhagen MF, Yurdakul G, Schröder FH, Blijenberg G, 2004

    Journal: BJUI
    Reference: 93: 720-724

    paper

  • 210. The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable

    Zackrisson B, Aus G, Bergdahl S, Lilja H, Lodding P, Pihl C-G, Hugosson J, 2004

    Journal: J Urol
    Reference: 171: 1500-1503

    paper

  • 209. Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio

    Aus G, Becker C, Franzen S, Lilja H, lodding P, Hugosson J, 2004

    Journal: Eur Urol
    Reference: 45: 160-165

    paper

  • 208. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma

    Hugosson J, Aus G, Lilja H, Lodding P, Pihl C-G, 2004

    Journal: Cancer
    Reference: 100: 1397-1405

    paper

  • 207. Prostaat-specifiek antigeen (PSA) 1984 – 2004

    Blijenberg BG, van Schaik RHN, 2004

    Journal: Analyse
    Reference: maart: 45-48

  • 206. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: Results of second screening round of ERSPC (Rotterdam)

    Roobol M.J, Kranse R, De Koning, H.J, Schröder F.H., 2004

    Journal: Urology
    Reference: 63(2):309-315

    paper

  • 205. Prostate-specific antigen change in the European randomized study of screening for prostate cancer, section Rotterdam

    Raaijmakers R, Wildhagen M.F, Ito K, Paèz A, De Vries S.H, Roobol M.J, Schröder F.H., 2004

    Journal: Urology
    Reference: 63(2):316-320

    paper

  • 204. Impact of radical prostatectomy and primary radiotherapy for localized prostate cancer on quality of life

    Essink-Bot M, Korfage I, de Koning H, 2003

    Journal: PACIOU VII, Panthenon
    Reference: p. 14-21

  • 203. Reliability of PSA testing remains unclear

    Ciatto S, 2003

    Journal: BMJ
    Reference: 339:30:00

  • 202. Effective PSA contamination in the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer

    Otto S.J, van der Cruijsen I.W, Liem M.K, Korfage I.J, Lous J.J, Schröder F.H, de Koning H.J., 2003

    Journal: Int. J. Cancer
    Reference: 105, 394-399

    paper

  • 201. Watchful waiting in prostate cancer: review and policy proposals

    Schröder FH, de Vries SH, Bangma CH, 2003

    Journal: BJUI
    Reference: 92:851-859

    paper

  • 200. Comparison of two assays for human kallikrein 2

    Blijenberg B.G, Wildhagen M.F, Bangma C.H, Finlay J.A, Vaisanen V, Schröder F.H., 2003

    Journal: Clin. Chem.
    Reference: Feb;49(2):243-247

    paper

  • 199. PSA-vergelijkbaarheid: standaardisatie of harmonisatie?

    van Zelst BD, Blijenberg BG, 2003

    Journal: Ned Tijdschr Klin Chem
    Reference: 28 (1) : 26-32

  • 198. Priorities in future research in prostate cancer screening

    Schröder FH, 2003

    Journal: Eur. J. Epid
    Reference: 18:1021-1023

    paper

  • 197. European Randomized study of Screening for Prostate Cancer: achievements and presentation

    Roobol MJ and Schröder FH, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 117-122

    paper

  • 196. Branding the ERSPC: a waste or a need?

    Denis LJ, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 115-116

    paper

  • 195. Monitoring the ERSPC trial

    de Koning HJ, Hakulinen T, Moss SM, Adolfsson J Smith PH, Alexander FE for the ERSPC, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 112-114

    paper

  • 194. MISCAN: estimating lead-time and over-detection by simulation

    Draisma G and de Koning HJ, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 106-111

    paper

  • 193. Including the quality-of-life aspects in the evaluation of prostate cancer screening: expert opinions revisited?

    Essink-Bot ML, Korfage IJ and de Koning HJ, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 101-105

    paper

  • 192. Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer Screening

    Ciatto S, Zappa M, Villers A, Paez A, Otto SJ and Auvinen A, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 97-100

    paper

  • 191. The clinical significance of a small focus of well-differentiated carcinoma at prostate biopsy

    Hoedemaeker RF, van der Kwast TH and Schröder FH, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 92-96

    paper

  • 190. Consistency of prostate cancer grading results in screened populations across Europe

    van der Kwast TH, Roobol MJ, Wildhagen MF, Martikainen PM, Määttänen L, Pihl C-G, Santonja C, Bubendorf L, Neetens I, Di Lollo S and Hoedemaeker RF, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 88-91

    paper

  • 189. Four-year prostate-specific antigen progression in the non-cancer population of the European Randomized Study of Screening for Prostate Cancer

    Paez A, Lujan M, Raaijmakers R, Berenguer A and members of ERSPC, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 84-87

    paper

  • 188. How to improve the specificity and sensitivity of biopsy technique in screening

    Ciatto S, Vis A and Finne P, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 79-83

    paper

  • 187. Quality assessment for prostate-specific antigen (PSA) in relation to ERSPC: report of the PSA Committee

    Blijenberg BG, Lilja H, Neels H and Stenman U-H, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 66-70

    paper

  • 186. Determining the cause of death in randomized screening trial(s) for prostate cancer

    de Koning HJ, Blom J, Merkelbach JW, Raaijmakers R, Verhaegen H, van Vliet P, Nelen V, Coebergh JW, Hermans A, Ciatto S and Mäkinen T, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 71-78

    paper

  • 185. Report of the Pathology Committee: false-positive and false-negative diagnoses of prostate cancer

    van der Kwast TH, Lopes C, Martikainen PM, Pihl C-G, Santonja C, Neetens I, Di Lollo S and Hoedemaeker RF, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 62-65

    paper

  • 184. The ERSPC Quality Control Committee

    Ciatto S, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 57-61

    paper

  • 183. The Data Monitoring Committee – bridging the gap between urology and public health epidemiology

    Smith PH, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 55-56

    paper

  • 182. Features and preliminary results of the Dutch centre of the ERSPC (Rotterdam, The Netherlands)

    Roobol MJ, Kirkels WJ and Schröder FH, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 48-54

    paper

  • 181. Features and preliminary results of prostate cancer screening in Canton Aargau, Switzerland

    Kwiatkowski M, Huber A, Stamm B, Lehmann K, Wernli M, Häfeli A and Recker F, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 44-47

    paper

  • 180. Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden

    Hugosson J, Aus G, Bergdahl S, Fernlund P, Frösing R, Lodding P, Pihl C-G and Lilja H, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 39-43

    paper

  • 179. The Spanish contribution to the European Randomized Study of Screening for Prostate Cancer

    Berenguer A, Lujan M, Paez A, Santonja C and Pascual T, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 33-38

    paper

  • 178. Specific features of the Italian section of the ERSPC

    Ciatto S, Gervasi G, Frullini P, Zendron P and Zappa M, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 30-32

    paper

  • 177. ERSPC: features and preliminary results of France

    Villers A, malavaud B, Rebillard X, Bataille V and Iborra F, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 27-29

    paper

  • 176. The Finnish trial of prostate cancer screening: where are we now?

    Finne P, Stenman U-H, Määttänen L, Mäkinen T, Tammela TLJ, Martikainen P, Ruutu M, Ala-Opas M, Aro J, Karhunen PJ, Lahtela J, Rissanen P, Juusela H, Hakama M and Auvinen A, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 22-26

    paper

  • 175. ERSPC: features and preliminary results of the Antwerp study centre

    Nelen V, Thys G, Neels H, neetnes I, Coebergh JW, Dourcy-Belle-Rose B and Denis LJ., 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 17-21

    paper

  • 174. The rationale for the ERSPC trial: will it improve the knowledge base on prostate cancer screening?

    Auvinen A and Hugosson J, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 14-16

    paper

  • 173. The story of the European Randomized Study of Screening for Prostate Cancer

    Schröder FH, Denis LJ, Roobol M and all participants of ERSPC, 2003

    Journal: BJUI
    Reference: Vol. 92, Suppl. 2: 1-13

    paper

  • 172. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.

    Hugosson J, Aus G, Lilja H, Lodding P, Pihl C.G, Pileblad E., 2003

    Journal: J. of Urol
    Reference: May;169(5):1720-3.

    paper

  • 171. Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer

    Becker C, Piironen T, Pettersson K, Hugosson J, Lilja H, 2003

    Journal: J. of Urol
    Reference: 170, 1169-1174

    paper

  • 170. Interval Carcinomas in the European Randomized Study of Screening for Prostate Cancer (ERSPC)–Rotterdam

    van der Cruijsen-Koeter I. W, van der Kwast T.H, Schröder F.H., 2003

    Journal: JNCI
    Reference: Vol. 95, 19, 1462-1466

    paper

  • 169. Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening.

    Zackrisson B, Aus G, Lilja H, Lodding P, Pihl C.G, Hugosson J., 2003

    Journal: Eur. Urol.
    Reference: Apr;43(4):327-32.

    paper

← PreviousNext →